Yorvipath denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Yorvipath as Not FDA-Approved — and How to Correct This

A "not FDA-approved" denial for Yorvipath (palopegteriparatide) most commonly reflects one of two situations: (1) a documentation or coding mismatch where Humana's system did not recognize the drug's approval status or the submitted indication, or (2) a policy application error where language written for truly unapproved or off-label uses was incorrectly applied to an on-label claim. In either case, this denial type is highly correctable on appeal because FDA approval is a matter of public record.

## Why This Is Appealable

FDA approval for Yorvipath in its approved indication is verifiable through the FDA's public labeling database. If the drug is being prescribed for the indication it is approved for, the denial rests on an incorrect factual premise. Appeals in this category succeed by presenting straightforward factual correction: the FDA-approved drug name, the approved indication, and confirmation that the patient's diagnosis matches that indication. The prescriber's letter should make this alignment explicit and unambiguous.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File a formal written internal appeal, clearly framing it as a factual correction rather than a clinical dispute. Request that a qualified clinical reviewer — not just a claims processor — review the appeal. Submit within the deadline stated on the denial notice.
• External review (ACA §2719): If the internal appeal is not resolved in your favor, escalate to an IRO. The IRO will evaluate whether the denial was correctly applied; factual errors are among the most straightforward IRO reversals. The external review window is generally up to four months.
• Expedited review: Available when delay poses a risk to the patient's health.

## Documentation to Gather

1. FDA label / prescribing information — download the current FDA-approved label for Yorvipath directly from the FDA website (Drugs@FDA). Highlight the approved indication and confirm it matches the patient's diagnosis. 2. Diagnosis confirmation — laboratory and clinical records establishing the patient's hypoparathyroidism diagnosis consistent with the FDA-approved indication. 3. Prescription and clinical records — confirm the prescriber ordered Yorvipath for the FDA-approved indication, and that the diagnosis codes submitted on the claim match that indication. 4. Prescriber cover letter — a brief, clear statement that (a) Yorvipath is FDA-approved, (b) the patient's diagnosis matches the approved indication, and (c) the prescription is on-label. 5. Claim resubmission review — work with the prescriber's billing staff to verify that diagnosis and procedure codes on the original claim were accurate; a coding error may have triggered the denial.

## Criteria-Mapping Strategy

This appeal is less about clinical criteria and more about factual accuracy. The cover letter should lead with: "This appeal respectfully asserts that Yorvipath (palopegteriparatide) holds FDA approval for [the patient's confirmed diagnosis]. The denial appears to rest on an incorrect determination of approval status." Attach the FDA label as Exhibit A. Attach the diagnosis documentation as Exhibit B. Keep the appeal concise — the facts speak for themselves.